VIP (Vasoactive Intestinal Peptide) is a signaling molecule the body uses across a surprisingly wide range of systems — the gut, lungs, immune system, brain, and internal clock. It generally acts as a calming, anti-inflammatory signal: relaxing smooth muscle, dampening immune overreaction, and helping the nervous system coordinate rest and recovery. Research has studied it for pulmonary arterial hypertension, inflammatory diseases, and neuroprotection, and it plays a foundational role in how the brain's circadian clock keeps time.
Pulmonary Arterial Hypertension Research
VIP has been studied for pulmonary arterial hypertension (PAH) — a condition involving progressive high blood pressure in the arteries of the lungs. Research shows VIP is deficient in PAH patients, and inhaled VIP has been studied as a treatment. Early studies showed improvements in exercise capacity and pulmonary artery pressures.
Anti-Inflammatory Research
VIP is a potent anti-inflammatory peptide. It inhibits the production of pro-inflammatory cytokines and promotes regulatory T-cell activity. Research has studied it in inflammatory bowel disease, rheumatoid arthritis, and sepsis models with positive anti-inflammatory results.
Circadian Rhythm and Sleep Research
VIP is one of the key neurotransmitters in the suprachiasmatic nucleus — the brain's master clock. It coordinates timing signals between individual circadian clock cells, synchronizing the daily rhythm across the brain. Without VIP, individual clock cells in the brain drift out of sync with each other — research on VIP has helped explain how the brain maintains a coherent daily rhythm across billions of cells rather than each one running on its own schedule.
Neuroprotection Research
VIP has neuroprotective properties, including protection against oxidative stress and amyloid beta toxicity relevant to Alzheimer's disease research. Animal studies show improved cognitive outcomes with VIP administration in neurodegeneration models.
Early human inhaled VIP studies in pulmonary arterial hypertension showed hemodynamic improvements.
Potent anti-inflammatory effects in multiple animal models of inflammatory disease.
Essential role in circadian rhythm synchronization established by basic science research.
Neuroprotective effects in Alzheimer's and other neurodegeneration animal models.
Short half-life limits clinical utility and requires specialized delivery systems.
VIP breaks down very quickly in circulation — within a couple of minutes — which is why standard injection approaches are not practical for most applications. Delivery systems designed to protect it or extend its activity are needed, and developing those is a significant focus of current research. The PAH research, while promising, has not advanced to a large phase 3 approval trial. It is not FDA-approved for any indication. Research use is primarily in understanding its biology and developing delivery approaches.
VIP is released from nerve endings throughout the body — in the gut, lungs, immune system, and brain — where it acts as both a neurotransmitter and a signaling hormone. It tells smooth muscle to relax (which dilates blood vessels and airways), tells immune cells to reduce inflammatory cytokine production, and coordinates the timing of circadian clock cells in the brain. In the gut, it regulates movement and fluid secretion. The breadth of its effects reflects its role as a general-purpose signaling molecule for the parasympathetic nervous system — the part of the nervous system associated with rest, digestion, and recovery. The same anti-inflammatory and relaxation effects that regulate normal physiology are what make it interesting as a potential treatment in conditions driven by excessive constriction or inflammation.
VIP has a very short half-life, which means its effects — including potential side effects like vasodilation and blood pressure lowering — are transient. Flushing, headache, and a temporary drop in blood pressure are the most commonly noted effects during administration — these reflect VIP's natural vasodilating action and typically resolve quickly. The short half-life paradoxically means rapid offset of effects, which can be favorable from a safety management perspective. It is not FDA-approved. Inhaled and intranasal delivery routes are under investigation to improve delivery while minimizing systemic effects.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
200ng/kg/min IV infusion; inhaled formulations in PAH studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Vasoactive Intestinal Peptide: A Neuropeptide with Pleiotropic Immune Functions
Behavioural interventions delivered through interactive social media for health behaviour change, health outcomes, and health equity in the adult population
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.